Development Of Cytokine-Inhibiting Gels For Treating Chronic Wounds
Award last edited on: 7/20/10

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
Newell R Washburn

Company Information

Washburn Therapeutics Inc

6743 Wilkins Avenue
Pittsburgh, PA 15217
Location: Single
Congr. District: 18
County: Allegheny

Phase I

Contract Number: 1R43GM085897-01A1
Start Date: 3/15/10    Completed: 9/14/10
Phase I year
Phase I Amount
Chronic wounds developed by patients with diabetes are becoming an increasing burden for Americans and our health care system. Diabetic foot ulcers cost tens of thousands of dollars to treat and are the leading cause of lower extremity amputation. While there is a broad range of treatment options available - ranging from debridement to application of recombinant platelet-derived growth factor - none has proven to be truly effective in treating this complex condition. The overall goal of this project is to develop a new biomaterial for treating chronic wounds that locally modulates the mediators of inflammation and promotes healing. The gels are composed of monoclonal antibodies that neutralize pro-inflammatory cytokines, such as tumor necrosis factor- 1, which have been covalently attached to hyaluronic acid gels. By covalently attaching cytokine-neutralizing antibodies to a hydrophilic gel, it is possible to locally modulate the inflammatory process - a critical component in the etiology of chronic wounds. Using a hyaluronic acid gels with established efficacy in treating chronic wounds provides an additional dimension of biological activity for improving healing in tandem with controlled neutralization of inflammatory mediators. Preliminary feasibility tests performed in a subcutaneous rat implantation model demonstrated that significant reductions in acute inflammation can be obtained through extensive neutralization of multiple cytokines. The goals in this Phase I research are (1) to identify gel formulations with minimal numbers of biologically active components that are still capable of modulating acute inflammation as determined using histology and immunohistochemical methods, (2) conduct dose-response experiments to determine the lowest antibody concentrations that still reduce inflammation, and (3) perform multiplex measurements of the injury-site concentrations of 14 mediators of inflammation to validate further the biological activities of the gels. This research program will provide necessary validation of the technology that will form the basis for further development and a Phase II application. Washburn Therapeutics will take forward the lead formulation identified in this research program to Phase II research involving tests on more accurate animal models of diabetic ulcers, pharmacokinetic studies on the systemic distribution of monoclonal antibodies, increases in susceptibility to infection, and toxicology studies. These studies will form the basis for developing a new class of therapeutics capable of modulating inflammatory responses and promoting the healing of chronic wounds.

Public Health Relevance:
Millions of patients with diabetes, sickle-cell anemia, pressure ulcers, and venous ulcers often develop non- healing wounds, which are painful, expensive to treat, and, in the case of diabetes, can be a major factor leading to lower extremity amputation. Washburn Therapeutics Inc. is developing a novel gel that inhibits the fundamental biochemical factors that sustain non-healing wounds and promotes healing.

Thesaurus Terms:
Acute; Address; American; Amputation; Animal Model; Animal Models And Related Studies; Animal Testing; Animals; Anti-Inflammatories; Anti-Inflammatory Agents; Anti-Inflammatory; Antibodies; Antiinflammatories; Antiinflammatory Agents; Assay; Becaplermin; Bed Sores; Bedsore; Bioassay; Biochemical; Biocompatible Materials; Biologic Assays; Biological; Biological Assay; Biological Factors; Biomaterials; Biosynthetic Proteins; Blood Circulation; Bloodstream; Body Tissues; Cachectin; Cachectin-Tumor Necrosis Factor; Cancers; Carboxymethyl Cellulose; Carboxymethylcellulose; Caring; Causality; Cell Communication And Signaling; Cell Signaling; Cell/Tissue, Immunohistochemistry; Characteristics; Chronic; Cicatrix; Circulation; Clinical; Clinical Trials; Clinical Trials, Phase I; Clinical Trials, Unspecified; Common Rat Strains; Complex; Cytokines, Chemotactic; Debridement; Decubitus Ulcer; Development; Diabetes Mellitus; Diabetic Foot Ulcer; Diabetic Ulcer; Dimensions; Dose; Drug Administration, Topical; Drug Formulations; Drug Kinetics; Early-Stage Clinical Trials; Encephalitis, Jc Polyomavirus; Etiology; Factor, Biologic; Formulation; Formulations, Drug; Foundations; Gfac; Gel; Goals; Growth Agents; Growth Factor; Growth Factors, Proteins; Growth Substances; Half-Life; Half-Lifes; Hb Ss Disease; Hbss Disease; Healed; Healing Abnormal; Healing Delayed; Healthcare Systems; Hemoglobin S Disease; Hemoglobin Sickle Cell Disease; Hemoglobin Sickle Cell Disorder; Histology; Homologous Chemotactic Cytokines; Hyaluronic Acid; Ihc; Inflm; Immune Response; Immunohistochemistry; Immunohistochemistry Staining Method; Impaired Healing; Impaired Tissue Repair; Impaired Wound Healing; Infection; Inflammation; Inflammation Mediators; Inflammatory; Inflammatory Response; Injury; Intercrines; Interleukins; Intracellular Communication And Signaling; Invaded; Jc Polyomavirus Encephalopathy; Janssen Brand Of Becaplermin; Lead; Legal Patent; Letters; Leukoencephalopathy, Progressive Multifocal; Licensing; Literature; Lower Extremity; Lower Limb; Malignant Neoplasms; Malignant Tumor; Mammals, Rats; Marketing; Measurement; Measures; Mediating; Membrum Inferius; Methods; Moab, Clinical Treatment; Modeling; Molecular Weight; Monoclonal Antibodies; Mortality; Mortality Vital Statistics; Natural Products; Pdgf; Pdgf-Bb; Pain; Painful; Patents; Patients; Pb Element; Pharmacokinetics; Phase; Phase 1 Clinical Trials; Phase I Clinical Trials; Phase I Study; Phenotype; Platelet-Derived Growth Factor; Platelet-Derived Growth Factor Beta Chain; Platlet-Derived Growth Factor Beta Chain; Polymers; Predisposition; Pressure Sore; Pressure Ulcer; Process; Production; Programs (Pt); Programs [publication Type]; Progressive Multifocal Leukoencephalopathy; Psoriasis; Raptiva; Rat; Rattus; Recombinant Platelet Derived Growth Factor Beta Chain; Recombinant Proteins; Recombinants; Regranex; Reporting; Research; Risk; Risk Factors; Sbir; Sbirs (R43/44); Sis Cytokines; Safety; Scars; Sickle Cell Anemia; Signal Transduction; Signal Transduction Systems; Signaling; Signaling Protein; Site; Small Business Innovation Research; Small Business Innovation Research Grant; Sprague-Dawley Rats; Structure; Susceptibility; Systems, Health Care; T-Cell Activation; Tnf (Unspecified); Tnf Receptor Ligands; Tnf-Alpha; Technology; Testing; Therapeutic; Therapeutic Agents; Therapeutic Antibodies; Time; Tissues; Topical Application; Toxicology; Tumor Necrosis Factor; Tumor Necrosis Factor Family Protein; Tumor Necrosis Factor-Alpha; Tumor Necrosis Factors; Ulcn; Ulcer; Ulceration; Universities; Validation; Varicose Ulcer; Venous Ulcer; Wound Healing; Wound Repair; Abnormal Tissue Repair; Base; Biological Signal Transduction; Chemoattractant Cytokine; Chemokine; Clinical Investigation; Cost; Cytokine; Delayed Wound Healing; Design; Designing; Diabetes; Diabetes Ulcer; Diabetic Patient; Disease Causation; Disease Etiology; Disease/Disorder Etiology; Disorder Etiology; Efalizumab; Experiment; Experimental Research; Experimental Study; Healing; Heavy Metal Pb; Heavy Metal Lead; Host Response; Immunoresponse; Implantation; Improved; In Vivo; Innovate; Innovation; Innovative; Macrophage; Malignancy; Model Organism; Neoplasm/Cancer; Neutralizing Antibody; Neutralizing Mab; Neutralizing Monoclonal Antibodies; Novel; Phase 1 Study; Phase 1 Trial; Phase I Trial; Platelet-Derived Growth Factor Bb; Prevent; Preventing; Programs; Protocol, Phase I; Psoriasiform; Psoriatic; Psoriatiform; Public Health Relevance; Research Study; Response; Rhpdgf-Bb; Safety Testing; Sickle Cell Disease; Sickle Disease; Sicklemia; Subcutaneous; Technological Innovation; Technology Development; Technology Validation; Therapeutic Protein; Tissue Repair; Topical Administration; Topical Drug Application; Topically Applied; Trafficking; Tumor Necrosis Factor (Unspecified); Unspecified Interleukin; Wound

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
Phase II Amount